Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer

Fig. 2

Association between FGFR3 Alteration and Molecular Subtypes. A Summary of FGFR3 alterations, FGFR3 mRNA expression, histological variant, consensus MIBC subtypes [6], UROMOL NMIBC subtypes [13], and Baylor college [14]. B Pie chart of FGFR3 alterations including recurrent mutations and fusions in 389 BLCA cases. C FGFR3 mRNA expression levels according to UROMOL subtypes. D FGFR3 mRNA expression levels according to consensus MIBC subtypes. E Estimated proportion of UROMOL subtypes in 124 NMIBC cases. F Estimated proportion of consensus MIBC subtypes in 265 MIBC cases. G Estimated proportion of consensus MIBC subtypes in 265 MIBC cases categorized based on FGFR3 mutational status (KD: kinase domain; note that seven cases with FGFR3 fusions were classified into mut- group)

Back to article page

Molecular Cancer

ISSN: 1476-4598